Human plasma dynamically quenches the fluorescein at the initial point of Oxygen Radical Absorption Capacity (ORAC) Assay

Harshi Prasadini Gunawardena (harshipg@wyb.ac.lk)
Wayamba University of Sri Lanka

Renuka Silva
Wayamba University of Sri Lanka - Makandura Campus

Pathmasiri Ranasinghe
Industrial Technology Institute

Research note

Keywords: ORAC assay, fluorescence, fluorescein, quenching, plasma biomolecule

Posted Date: December 11th, 2019

DOI: https://doi.org/10.21203/rs.2.13544/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on December 16th, 2019. See the published version at https://doi.org/10.1186/s13104-019-4845-4.
Abstract

Objective: Oxygen Radical Absorbance Capacity (ORAC) assay measures the quenching of fluorescent probe by peroxyl radicals. Antioxidants present in biological systems block the quenching of fluorescence probe. We experienced dynamic quenching of fluorescein in ORAC assay by human plasma while plasma ORAC assay was optimized. Therefore, for the first time, we report the quenching of fluorescein by plasma at the initial point of ORAC assay.

Results: Aqueous whole and non-protein fractions of plasma were used in the analysis. Since both fractions showed a similar pattern of quenching at the initial stage, quenched percentage of fluorescein was calculated and added to each sample in subsequent analysis. Addition of extra 20% fluorescein allowed plasma samples to quench the required amount of fluorescein and follow normal decay curves afterwards. Further, change of fluorescein quenching ($\Delta F/F_0$) disclosed a dose dependent linear relationship with plasma ($R^2 = 0.8$). It can be speculated that dynamic quenching exhibited by human plasma biomolecule/s at the initial stage would be of non-protein aqueous phase molecule/s. We suggest initiating further studies to detect, identify and quantify the fluorescein quenching biomolecules present in human plasma for further improvements in plasma ORAC assay.

Introduction

The Oxygen Radical Absorbance Capacity (ORAC) assay is a widely accepted method of measuring the antioxidant capacity of different biological samples. It is based upon the early work of Ghiselli et al. [1] and Glazer [2], and developed further by Cao et al. [3]. ORAC measures inhibition of peroxyl radical induced oxidation by the antioxidants and therefore, reflects classical radical chain breaking antioxidant activity by H atom transfer [4]. Peroxyl radicals are formed by a free radical initiator. Peroxyl radicals subsequently react with a fluorescent probe such as fluorescein to form a non-fluorescent product, which can be quantified easily by fluorescence. In this assay, both the inhibition time and the inhibition percentage of free radical damage are taken into a single value [5]. Antioxidants present in experimental sample can delay the oxidation of fluorescent probe by the peroxyl radicals until their antioxidant activity get depleted. Therefore, the area under the curve (AUC) of the fluorescence decay curve is used to quantify the total antioxidant activity against the peroxyl radical in the sample compared to the standard curve of water soluble vitamin E analog Trolox.

Interestingly, we found that the human plasma samples initially tend to quench the fluorescence exerted by fluorescein when we tried to optimize the plasma ORAC assay. After the dynamic quenching of fluorescein at initial point, plasma samples followed normal fluorescence decay curves. Fluorescein quenching of human plasma was appeared to be quite significant. This has not been specifically studied or previously reported in literature. Therefore, the present study was conducted to assess the initial dynamic fluorescence quenching exerted by human plasma.

Materials And Methods
Subjects and methods

Seventy six ($n = 76$) type 2 diabetic patients and eighty ($n = 80$) normoglycaemic healthy volunteers were recruited to this cross sectional study. Fasting venous blood samples were collected using lithium heparin as the anticoagulant. Plasma separation was carried out in a centrifuge ((TOMOS 3–18R High speed refrigerated centrifuge, Tomos Life Science Group, USA) set at 4000 rpm for 20 minutes. Plasma aliquots were stored at $–80^{0}C$ until the analysis.

Plasma ORAC assay

Plasma aqueous phase ORAC assay was determined based on the original method of Cao and Prior in 1999 [6] with the modifications [4]. ORAC assay was conducted at $37^{0}C$ using fluorescein as the substrate and AAPH (2,2-azobis (2-amidinopropane) dihydrochloride (Sigma Aldrich, Germany) as the oxidant generator. The assay buffer, Phosphate Buffered Saline (PBS) was used as the blank. Following the centrifugation, plasma supematant was diluted with phosphate buffered saline (PBS) in 1:80 ratio. Ten micro liters (10µL) of the standard or diluted samples in triplicate, 100µL of fluorescein and 40 µL of 75 mM PBS were mixed in 96 well black plates and mixed well. Then the reaction mixtures were incubated at $37^{0}C$ in Micro-plate Reader (Spectra Max Gemini, Germany) for 30 minutes prior to addition of 50 µL of AAPH. After achieving the complete mixing, plate was placed in the Fluorescence Micro plate Reader and kinetic reads were performed at 60 seconds intervals for 35 cycles at excitation wavelength of 494 nm and an emission wavelength of 535nm. Fluorescein decay curves were based on individual well fluorescence relative to the initial value and derived net area under the each curve (NAUC) at 1 minute intervals. NAUC of standards were used to derive the standard curve. Data were expressed as antioxidant activity in Trolox equivalents based on above derived standard curve. One ORAC unit was defined as the net protection area provided by 1µM final concentration of Trolox.

Results

Dynamic fluorescein quenching by plasma

In the plasma ORAC assay, steady quenching of fluorescence exhibited by fluorescein over the period of time (35 cycles) monitored at 1 minute intervals. However, plasma of both diabetic and normoglycaemic healthy individuals tends to quench a significant amount of fluorescein dynamically at the initial stage. Therefore, it could suspect the presence of a compound or biomolecule of plasma with the potential of dynamic quenching of fluorescence exerted by fluorescein as illustrated in Figure 1. Further, the potent compound or biomolecule let the decay curves to be followed afterwards (Figure 1). It was indicated in the static quenching of fluorescence over the rest of 35 cycles of the assay.
With the limited laboratory facilities, we were unable to detect the potent compound or biomolecule present in plasma with dynamic quenching properties. However, there are no any studies or published data on human serum/plasma albumin or any other protein or biomolecule present in human plasma on quenching the fluorescence emitted by fluorescein. Nevertheless, to avoid any possible interference exerted by the plasma proteins, non-protein fraction of the plasma was extracted using perchloric acid (plasma: perchloric acid, 1:1 ratio) and used in the subsequent analysis. However, fluorescence quenching of plasma non-protein fraction was similar to that of the plasma fraction with proteins. Hence, we can assume that the quenching is not exerted fully or partly by proteins present human plasma.

As illustrated in Figure 1, it has observed that the quenching was stable after the initial point of ORAC assay (t = 0 sec) and towards the rest of the 35cycles (t = 2100 sec) of ORAC assay over the time. Meanwhile, the initial quenching was dynamic and the change in quenching over the time (35 min) was static, percentage of fluorescence quenched by plasma samples were calculated and added that amount of fluorescein to the each well (100µL+% fluorescein quenched). Calculated percentage of fluorescein to be added to the initial volume was 16–20%. Addition of 120 µL of fluorescein gave required initial relative fluorescence units (RFU) allowing 20% to be quenched and follow the normal fluorescence decay curves as shown in Figure 2. Therefore, addition of 20 µL was continued in the analysis.

Dose dependency and linearity characteristics of dynamic plasma quenching were further studied using a dilution series. Dilution series of plasma as 10, 20, 40, 80, 160 and 200 were used to assess the dose dependency and it is illustrated in Figure 3. After calculating the change of relative fluorescence units (RFU) at t = 0 of each of dilution series, it was plotted against the dilution to check the linearity of quenching and it was 0.76. Change in RFU with dilution series resembles that the quenching of fluorescence by the plasma molecule was dependent on its concentration. Hence it suggests the presence of significant linear relationship between the concentration of plasma quencher with the fluorescence quenching.

Discussion

In the ORAC assay, oxidative degradation or quenching of fluorescence probe by the peroxyl radicals is assessed. Antioxidants can delay the quenching of fluorescence probe by peroxyl radicals. Therefore, time taken for quenching the fluorescent probe may vary depending on the antioxidant potential of the sample. Hence, in this assay, both the inhibition time and the inhibition percentage of free radical damage are taken into a single value [5]. Fluorescence quenching detects as the decline in fluorescence intensity of sample. A variety of molecular interactions can result in quenching such as excited-state reactions, molecular rearrangements, energy transfer, ground state complex formation and collisional quenching.

In fact the fluorescence quenching is used in the ORAC assay, this is the first time we report the dynamic quenching of fluorescence given by fluorescein in plasma analysis. Similar pattern of dynamic quenching exhibited for plasma of both diabetic and healthy individuals indicates the presence of a common biomolecule or compound. Although the evidence on fluorescence quenching by plasma proteins is not
available, frequent use of quenching process in examining, the structural and functional properties of proteins has been reported previously [7,8]. In eliminating any possible interference by plasma proteins, steps were taken to analyze the non-protein fraction of plasma. Aqueous non-protein fraction of the plasma was extracted using equal volumes of plasma and perchloric acid. However, our findings have shown that the non-protein fraction of plasma followed the same pattern of quenching as whole plasma. Therefore, we can infer that the quenching is not partly or fully imparted by plasma proteins. Other potential fluorescence quenchers present in human plasma are found to be molecular oxygen [9–14] and uric acid derivatives like porphyrin uric acid [15]. However, we could not recognize the molecule due to lack of facilities.

According to our findings, addition of extra fluorescein has shown to be effective in addressing the dynamic quenching by plasma. Hence, it was further confirmed that compound or biomolecule present in plasma quenches exact percentage of fluorescence provided by extra fluorescein. Plasma dilution series exhibited that the fluorescence quenching was dose dependent.

Although we were unable to identify the molecule present in the plasma with fluorescence quenching activity, we could suspect it as a molecule common for both diabetics and healthy people. Since the non-protein fraction followed the same pattern of quenching as whole plasma, it is confirmed that the quenching is not partly or fully imparted by plasma proteins. As the lipid phase extraction was not carried out in ORAC analysis, it can be predicted that the molecule or the compound of interested would be a water soluble one. It followed the dynamic fluorescence quenching at the initial point and exhibited static fluorescence quenching in rest of the assay. Therefore, further analysis and study of the compound or biomolecule present in the human plasma responsible for quenching would be of great importance.

**Conclusion**

Fluorescence quenching by human plasma in ORAC assay was observed for the first time. Both diabetic and healthy individuals tend to have the similar pattern of fluorescence quenching. Dynamic fluorescence quenching taken place at the aqueous phase ORAC assay speculate that the interested quenching compound or biomolecule would be of water soluble nature. A significant linear relationship between the fluorescence quenching and concentration of the plasma quencher was observed. However, further analysis of fluorescence quenching by the interested molecule would be of great importance in improving the plasma ORAC assay.

**Limitations**

We were not able to identify the interested biomolecule or compound responsible for dynamic quenching of fluorescein at the initial point of plasma ORAC assay due to unavailability of laboratory facilities.

In fact, we could not able to identify and quantify the biomolecule or compound responsible for dynamic quenching, only the possible interference was minimized by adding extra fluorescein.
Only we could infer the nature of interested biomolecule or compound as it is a water soluble and common molecule for both diabetic and healthy individuals.

Although the non-protein fraction demonstrated the similar pattern of dynamic quenching as whole plasma, contribution of protein derivatives might have interfered.

**List Of Abbreviations**

AUC—Area under the curve

NAUC- Net area under the curve

ORAC—Oxygen radical absorption capacity

RFU—Relative fluorescence units

**Declarations**

**Ethics approval and consent to participate**

The study protocol was approved by the Ethics Review Committee of Sri Lanka Medical Association (ERC/07/007). Written informed consent was obtained from each participant after providing the detailed description of the study. The study was designed in compliance with the Declaration of Helsinki.

**Consent for publication**

Since the individual details, images or videos are not included in the manuscript, consent to publication is not applicable for this manuscript.

**Availability of data and material**

The datasets analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**
National Research Council of Sri Lanka (NRC Grant No: 09–48) provided the financial assistance in designing the study, data collection and analysis.

**Author’s contributions**

HG, RS and PR made substantial contribution to the conception and study design. HG and RS were involved in data collection. HG, RS and PR were involved in refining the study design, sample analysis and drafting the manuscript. HG and RS critically revised the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

All subjects are kindly acknowledged for their voluntary participation. We express appreciation for research teams of Department of Applied Nutrition, Wayamba University of Sri Lanka and Herbal Technology Division, Industrial Technology Institute for their assistance.

**Authors’ information**

Harshi Gunawardena and Renuka Silva

Affiliations

Department of Applied Nutrition, Wayamba University of Sri Lanka, Makandura, Gonawila (NWP), Sri Lanka

Pathmasiri Ranasinghe

Affiliations

Herbal Technology Division, Industrial Technology Institute, Sri Lanka

Corresponding author

Correspondence to Harshi Gunawardena

**References**


Figures
Figure 1

Dynamic fluorescence quenching of plasma of type 2 diabetic patients and healthy controls [Segment A_Fluorescein solution in the absence of AAPH; Segment B_Fluorescence decay curves of fluorescein in the absence of plasma; Segment C_Fluorescence decay curves of fluorescein in the presence of human plasma; D_Dynamic quenching of fluorescein solution by the plasma of both diabetic and healthy subjects at the initial point]
Figure 2

Fluorescence decay curves of plasma of diabetic patients and healthy subjects after correcting for dynamic quenching by adding extra 20μL of fluorescein [Segment A_Fluorescein solution in the absence of AAPH; Segment B_Fluorescein solution in the absence of plasma; Segment C_Fluorescein solution in the presence of human plasma + addition of 20μL of extra fluorescein]
Figure 3

Dose dependent relationship exhibited by the different dilutions of human plasma with fluorescence decay

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- ORACpapermodifiedon29thNov.pdf